Capital World Investors Rubius Therapeutics, Inc. Transaction History

Capital World Investors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $424,072 - $3.21 Million	-536,800 Reduced 19.51%	2,214,200 $1.88 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $968,000 - $1.77 Million	100,000 Added 3.77%	2,751,000 $26.6 Million
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $21.1 Million - $31.1 Million	1,200,667 Added 82.79%	2,651,000 $47.4 Million
Q1 2021 May 14, 2021	BUY	$8.02 - $32.01 $2.67 Million - $10.7 Million	333,333 Added 29.84%	1,450,333 $38.4 Million
Q2 2020 Aug 14, 2020	SELL	$4.01 - $6.88 $2.59 Million - $4.44 Million	-645,598 Reduced 36.63%	1,117,000 $6.68 Million
Q1 2020 May 15, 2020	SELL	$3.74 - $9.84 $12.8 Million - $33.6 Million	-3,414,402 Reduced 65.95%	1,762,598 $7.84 Million
Q4 2019 Feb 18, 2020	BUY	$7.23 - $14.12 $15.3 Million - $29.9 Million	2,114,604 Added 69.05%	5,177,000 $49.2 Million
Q4 2018 Feb 14, 2019	BUY	$13.83 - $22.97 $2.35 Million - $3.9 Million	170,000 Added 5.88%	3,062,396 $48.1 Million
Q3 2018 Nov 14, 2018	BUY	$20.06 - $26.94 $58 Million - $77.9 Million	2,892,396 New	2,892,396 $67.9 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.